The Oncology Institute, Inc.

DFPH

CIK 0001799191 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$142M
↑+41.6% +$42Mvs FY2024 (Q4)
Operating Income
$112M
↑+52.4% +$39Mvs FY2024 (Q4)
Net Income
$110M
↑+52.2% +$38Mvs FY2024 (Q4)
Gross Profit
$142M
↑+41.6% +$42Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
76/100
  • Profitability
    0ROIC -36.0% (10% = solid, 20%+ = moat)
  • Liquidity
    54Current Ratio 1.59 (above 1.5 = solid)
  • Leverage
    100D/E -4.92 (under 0.5 = conservative)
  • Efficiency
    100Asset Turnover 2.98x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +41.6% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -5.9% · trend +8.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$3M
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$5M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$165M
everything owned
Total liabilities
$180M
everything owed
Stockholders' equity
$-16M
shareholder claim
Net debt
$77M
LT debt minus cash

Recent performance · 25 quarters

Revenue↑+41.6% +$42M
$142M
Net Income↓-2.4% -$391K
$-17M
Free Cash Flow↓-3.2% -$72K
$2M
Operating Margin↑+8.0pts
-5.9%

Drill down